Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis

Osteoarthritis and Cartilage

Volumn 16, Issue 12, 2008, Pages 1484-1493

  Alvarez Soria M A ^a   Herrero Beaumont, G ^a   Moreno Rubio, J ^a   Calvo, E ^a   Santillana, J ^b   Egido, J ^a   Largo, R ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Hospital Virgen de la Cinta   (Spain)

Author keywords

Articular cartilage; Celecoxib; COX 2; NSAID; Osteoarthritis

Indexed keywords

ACECLOFENAC; CELECOXIB; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KNEE OSTEOARTHRITIS; LONG TERM CARE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TOTAL KNEE REPLACEMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE, ARTICULAR; CHONDROCYTES; CYCLOOXYGENASE 2; DICLOFENAC; DINOPROSTONE; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-1; MALE; NITRIC OXIDE; OSTEOARTHRITIS, KNEE; PYRAZOLES; SULFONAMIDES; SYNOVIAL MEMBRANE;

EID: 55349126753     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.04.022     Document Type: Article

References (49)

1. Stadler J., Stefanovic-Racic M., Billiar T.R., Curran R.D., McIntyre L.A., Georgescu H.I., et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 147 (1991) 3915-3920
2. Vincenti M.P., Coon C.I., Lee O., and Brinckerhoff C.E. Regulation of collagenase gene expression by IL-1 beta requires transcriptional and post-transcriptional mechanisms. Nucleic Acids Res 22 (1994) 4818-4827
3. Morisset S., Patry C., Lora M., and de Brum-Fernandes A.J. Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17-beta-estradiol. J Rheumatol 25 (1998) 1146-1153
4. Stichtenoth D.O., Thoren S., Bian H., Peters-Golden M., Jakobsson P.J., and Crofford L.J. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 167 (2001) 469-474
5. Benton H.P., and Tyler J.A. Inhibition of cartilage proteoglycan synthesis by interleukin I. Biochem Biophys Res Commun 154 (1988) 421-428
6. Tyler J.A., and Benton H.P. Synthesis of type II collagen is decreased in cartilage cultured with interleukin 1 while the rate of intracellular degradation remains unchanged. Coll Relat Res 8 (1988) 393-405
7. Evans C.H. Nitric oxide: what role does it play in inflammation and tissue destruction?. Agents Actions Suppl 47 (1995) 107-116
8. Murrell G.A., Jang D., and Williams R.J. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 206 (1995) 15-21
9. Taskiran D., Stefanovic-Racic M., Georgescu H., and Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 200 (1994) 142-148
10. Melchiorri C., Meliconi R., Frizziero L., Silvestri T., Pulsatelli L., Mazzetti I., et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 41 (1998) 2165-2174
11. Hashimoto S., Takahashi K., Ochs R.L., Coutts R.D., Amiel D., and Lotz M. Nitric oxide production and apoptosis in cells of the meniscus during experimental osteoarthritis. Arthritis Rheum 42 (1999) 2123-2131
12. Martel-Pelletier J., Pelletier J.P., and Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 33 (2003) 155-167
13. Goldring M.B., and Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 427 (2004) S37-S46
14. Bonnet C.S., and Walsh D.A. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44 (2005) 7-16
15. Dingle J.T. Prostaglandins in human cartilage metabolism. J Lipid Mediat 6 (1993) 303-312
16. DiBattista J.A., Pelletier J.P., Zafarullah M., Fujimoto N., Obata K., and Martel-Pelletier J. Coordinate regulation of matrix metalloproteases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts. J Rheumatol 43 (1995) 123-128
17. Mastbergen S.C., Lafeber F.P., and Bijlsma J.W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 41 (2002) 801-808
18. El Hajjaji H., Marcelis A., Devogelaer J.P., and Manicourt D.H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 30 (2003) 2444-2451
19. Mastbergen S.C., Bijlsma J.W., and Lafeber F.P. Selective COX-2 inhibition is favorable to human early and late-stage osteoarthritic cartilage: a human in vitro study. Osteoarthritis Cartilage 13 (2005) 519-526
20. Sugimoto Y., and Narumiya S. Prostaglandin E receptors. J Biol Chem 282 (2007) 11613-11617
21. Towheed T., Shea B., Wells G., and Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev (1997) CD000517
22. Alvarez-Soria M.A., Largo R., Santillana J., Sanchez-Pernaute O., Calvo E., Hernandez M., et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 65 (2006) 998-1005
23. Mankin H.J., Dorfman H., Lippiello L., and Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 53 (1971) 523-537
24. Largo R., Alvarez-Soria M.A., Díez-Ortego I., Calvo E., Sanchez-Pernaute O., Egido J., et al. Glucosamine inhibits IL-1beta-induced NFkB activation. Osteoarthritis Cartilage 11 (2003) 290-298
25. Yamazaki R., Kawai S., Matsuzaki T., Kaneda N., Hashimoto S., Yokokura T., et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 329 (1997) 181-187
26. Clemett D., and Goa K.L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59 (2000) 957-980
27. Todd P.A., and Sorkin E.M. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 35 (1988) 244-285
28. Largo R., Díez-Ortego I., Sanchez-Pernaute O., Lopez-Armada M.J., Alvarez-Soria M.A., Egido J., et al. EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts. Ann Rheum Dis 63 (2004) 1197-1204
29. Hardy M.M., Seibert K., Manning P.T., Currie M.G., Woerner B.M., Edwards D., et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46 (2002) 1789-1803
30. Takada Y., Bhardwaj A., Potdar P., and Aggarwal B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 9 (2004) 9247-9258
31. Shishodia S., Koul D., and Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173 (2004) 2011-2022
32. Pelletier J.P., Fernandes J.C., Jovanovic D.V., Reboul P., and Martel-Pelletier J. Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. J Rheumatol 28 (2001) 2509-2519
33. Henrotin Y., de Leval X., Mathy-Hartet M., Mouithys-Mickalad A., Deby-Dupont G., Dogne J.M., et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 50 (2001) 391-399
34. Mastbergen S.C., Bijlsma J.W., and Lafeber F.P. Synthesis and release of human cartilage matrix proteoglycans are differently regulated by nitric oxide and prostaglandin-E2. Ann Rheum Dis 67 1 (2008) 52-58
35. Sanchez C., Mateus M.M., Defresne M.P., Crielaard J.M., Reginster J.Y., and Henrotin Y.E. Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs. J Rheumatol 29 (2002) 772-782
36. Faour W.H., He Y., He Q.W., de Ladurantaye M., Quintero M., Mancini A., et al. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 276 (2001) 31720-31731
37. Kojima F., Naraba H., Sasaki Y., Beppu M., Aoki H., and Kawai S. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 48 (2003) 2819-2828
38. Batlle-Gualda E., Román Ivorra J., Martín-Mola E., Carbonell Abelló J., Linares Ferrando L.F., Tornero Molina J., et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarthritis Cartilage 15 (2007) 900-908
39. Bort R., Ponsoda X., Carrasco E., Gómez-Lechón M.J., and Castell J.V. Metabolism of aceclofenac in humans. Drug Metab Dispos 24 (1996) 834-841
40. Yamazaki R., Kawai S., Matsumoto T., Matsuzaki T., Hashimoto S., Yokokura T., et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 289 (1999) 676-681
41. Brochhausen C., Neuland P., Kirkpatrick C.J., Nusing R.M., and Klaus G. Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ - prostaglandin E2 dependent proliferation of growth plate chondrocytes. Arthritis Res Ther 8 (2006) R78
42. Del Toro Jr. F., Sylvia V.L., Schubkegel S.R., Campos R., Dean D.D., Boyan B.D., et al. Characterization of prostaglandin E(2) receptors and their role in 24,25-(OH)(2)D(3)-mediated effects on resting zone chondrocytes. J Cell Physiol 182 (2000) 196-208
43. McCoy J.M., Wicks J.R., and Audoly L.P. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110 (2002) 651-658
44. Honda T., Segi-Nishida E., Miyachi Y., and Narumiya S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203 (2006) 325-335
45. Matsuda K., Nakamura S., and Matsushita T. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int 26 (2006) 991-995
46. Smith M.D., Triantafillou S., Parker A., Youssef P.P., and Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 24 (1997) 365-371
47. Pelletier J.P., DiBattista J.A., Roughley P., McCollum R., and Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 19 (1993) 545-568
48. Marks P.H., and Donaldson M.L. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 21 (2005) 1342-1347
49. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 (2001) 2057-2072